vs
Side-by-side financial comparison of Avantor, Inc. (AVTR) and Prenetics Global Ltd (PRE). Click either name above to swap in a different company.
Avantor, Inc. is the larger business by last-quarter revenue ($1.7B vs $4.3M, roughly 387.3× Prenetics Global Ltd).
Avantor, Inc. is an American biotechnology, chemicals, and pharmaceutical company headquartered in Radnor, Pennsylvania. Established in 1904 as J.T. Baker, the company changed its name to Avantor in 2010. Avantor went public in 2019 and is now listed on the New York Stock Exchange under the symbol “AVTR”.
Prenetics (NASDAQ:PRE) is a health sciences company headquartered in Hong Kong, with a presence in the United States. It focuses on early detection, prevention, and treatment of diseases, particularly cancer.
AVTR vs PRE — Head-to-Head
Income Statement — Q4 2025 vs Q3 2023
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $4.3M |
| Net Profit | $52.4M | — |
| Gross Margin | 31.5% | 44.9% |
| Operating Margin | 7.6% | -396.2% |
| Net Margin | 3.1% | — |
| Revenue YoY | -1.4% | — |
| Net Profit YoY | -89.5% | — |
| EPS (diluted) | $0.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | — |
| Q4 25 | $52.4M | — | ||
| Q3 25 | $-711.8M | — | ||
| Q2 25 | $64.7M | — | ||
| Q1 25 | $64.5M | — | ||
| Q4 24 | $500.4M | — | ||
| Q3 24 | $57.8M | — | ||
| Q2 24 | $92.9M | — | ||
| Q1 24 | $60.4M | — |
| Q4 25 | 31.5% | — | ||
| Q3 25 | 32.4% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 33.8% | — | ||
| Q4 24 | 33.4% | — | ||
| Q3 24 | 32.9% | — | ||
| Q2 24 | 34.1% | — | ||
| Q1 24 | 34.0% | — |
| Q4 25 | 7.6% | — | ||
| Q3 25 | -40.0% | — | ||
| Q2 25 | 7.7% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 37.8% | — | ||
| Q3 24 | 7.3% | — | ||
| Q2 24 | 10.3% | — | ||
| Q1 24 | 8.7% | — |
| Q4 25 | 3.1% | — | ||
| Q3 25 | -43.8% | — | ||
| Q2 25 | 3.8% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 29.7% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 3.6% | — |
| Q4 25 | $0.08 | — | ||
| Q3 25 | $-1.04 | — | ||
| Q2 25 | $0.09 | — | ||
| Q1 25 | $0.09 | — | ||
| Q4 24 | $0.73 | — | ||
| Q3 24 | $0.08 | — | ||
| Q2 24 | $0.14 | — | ||
| Q1 24 | $0.09 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $365.4M | — |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $5.6B | — |
| Total Assets | $11.8B | — |
| Debt / EquityLower = less leverage | 0.71× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $365.4M | — | ||
| Q3 25 | $251.9M | — | ||
| Q2 25 | $449.4M | — | ||
| Q1 25 | $315.7M | — | ||
| Q4 24 | $261.9M | — | ||
| Q3 24 | $285.3M | — | ||
| Q2 24 | $272.6M | — | ||
| Q1 24 | $234.9M | — |
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
| Q4 25 | $5.6B | — | ||
| Q3 25 | $5.6B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $6.1B | — | ||
| Q4 24 | $6.0B | — | ||
| Q3 24 | $5.6B | — | ||
| Q2 24 | $5.4B | — | ||
| Q1 24 | $5.3B | — |
| Q4 25 | $11.8B | — | ||
| Q3 25 | $11.7B | — | ||
| Q2 25 | $12.8B | — | ||
| Q1 25 | $12.3B | — | ||
| Q4 24 | $12.1B | — | ||
| Q3 24 | $12.8B | — | ||
| Q2 24 | $12.7B | — | ||
| Q1 24 | $12.8B | — |
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $152.7M | — |
| Free Cash FlowOCF − Capex | $117.2M | — |
| FCF MarginFCF / Revenue | 7.0% | — |
| Capex IntensityCapex / Revenue | 2.1% | — |
| Cash ConversionOCF / Net Profit | 2.91× | — |
| TTM Free Cash FlowTrailing 4 quarters | $495.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $152.7M | — | ||
| Q3 25 | $207.4M | — | ||
| Q2 25 | $154.4M | — | ||
| Q1 25 | $109.3M | — | ||
| Q4 24 | $173.3M | — | ||
| Q3 24 | $244.8M | — | ||
| Q2 24 | $281.1M | — | ||
| Q1 24 | $141.6M | — |
| Q4 25 | $117.2M | — | ||
| Q3 25 | $171.7M | — | ||
| Q2 25 | $124.8M | — | ||
| Q1 25 | $81.3M | — | ||
| Q4 24 | $145.8M | — | ||
| Q3 24 | $204.0M | — | ||
| Q2 24 | $235.3M | — | ||
| Q1 24 | $106.9M | — |
| Q4 25 | 7.0% | — | ||
| Q3 25 | 10.6% | — | ||
| Q2 25 | 7.4% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 8.6% | — | ||
| Q3 24 | 11.9% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 6.4% | — |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
PRE
Segment breakdown not available.
